BLU-285 for advanced systemic mastocytosis

Bookmark and Share
Published: 10 Dec 2017
Views: 2225
Rating:
Save
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA

Prof DeAngelo talks with ecancer at the 2017 ASH annual meeting about the phase 1 study of BLU-285, a highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis. 

Prof DeAngelo highlights that BLU-285 demonstrated significant clinical activity across all dose levels, with rapid and durable reductions in mast cell burden and D816V mutant allele fraction relative to baseline.

Read the news story or watch the press conference for more.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.